文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

静脉血管紧张素Ⅱ给药的安全性的系统评价

Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论系统评价显示静脉血管紧张素Ⅱ不良事件不常见,但加重哮喘和心力衰竭及一例致命脑出血曾被报告,该药在人体使用具有可接受的安全性。

本研究为系统评价,筛选18468项研究,最终纳入1124项研究、31281名接受静脉血管紧张素Ⅱ(0.5-3780 ng/kg/min)的受试者。常见非升压效应包括血浆醛固酮、肾功能、心脏变量和电解质变化;不良事件不常见,包括头痛、胸部压迫感和直立症状。最严重的副作用是加重充血性心力衰竭患者的左心室衰竭和支气管收缩,一例充血性心力衰竭患者死于难治性左心室衰竭;病例研究、队列研究和一项安慰剂对照研究中,115例接受血管紧张素Ⅱ治疗的难治性低血压休克患者中55例死亡;一名健康受试者连续输注升压剂量血管紧张素Ⅱ 6天后死亡。结论认为血管紧张素Ⅱ不良事件不常见,但曾报告加重哮喘和充血性心力衰竭及一例致命脑出血;该系统评价支持血管紧张素Ⅱ在人体使用具有可接受的安全性。

要点

  • 系统评价纳入1124项研究、31281名受试者,静脉血管紧张素Ⅱ剂量范围0.5-3780 ng/kg/min,不良事件不常见。
  • 最严重副作用为加重充血性心力衰竭患者的左心室衰竭和支气管收缩,一例充血性心力衰竭患者死于难治性左心室衰竭。
  • 病例研究、队列研究和一项安慰剂对照研究中,115例难治性低血压休克患者接受血管紧张素Ⅱ治疗,55例死亡。
  • 一名健康受试者连续输注升压剂量血管紧张素Ⅱ 6天后死亡;另报告一例致命脑出血。
  • 研究设计异质性妨碍了荟萃分析,该系统评价支持血管紧张素Ⅱ在人体使用具有可接受的安全性。

适用人群与场景

  • 接受静脉血管紧张素Ⅱ的人体研究受试者,包括健康受试者及患有充血性心力衰竭、难治性低血压休克等疾病的患者。

红旗征与不能漏的情况

  • 充血性心力衰竭患者使用血管紧张素Ⅱ可能加重左心室衰竭,一例患者死于难治性左心室衰竭。
  • 血管紧张素Ⅱ可能引起支气管收缩,加重哮喘。
  • 曾报告一例致命脑出血与血管紧张素Ⅱ相关。

研究设计与关键结果

  • 系统评价筛选18468项研究,最终纳入1124项研究,共31281名受试者接受静脉血管紧张素Ⅱ(0.5-3780 ng/kg/min)。
  • 常见非升压效应包括血浆醛固酮、肾功能、心脏变量和电解质变化;不良事件不常见,包括头痛、胸部压迫感和直立症状。
  • 最严重副作用为加重充血性心力衰竭患者的左心室衰竭和支气管收缩;一例充血性心力衰竭患者死于难治性左心室衰竭。
  • 病例研究、队列研究和一项安慰剂对照研究中,115例难治性低血压休克患者接受血管紧张素Ⅱ治疗,其中55例死亡。
  • 一名健康受试者连续输注升压剂量血管紧张素Ⅱ 6天后死亡;未报告其他归因于血管紧张素Ⅱ的严重不良事件。
  • 研究设计异质性妨碍了荟萃分析。

证据类型、等级与局限

  • 证据类型:系统评价;检索PubMed、Medline、Scopus和Cochrane数据库。
  • 局限:研究设计异质性妨碍了荟萃分析。

对床旁实践的改变

  • 该系统评价支持血管紧张素Ⅱ在人体使用具有可接受的安全性,但需警惕加重充血性心力衰竭和支气管收缩,并注意曾报告一例致命脑出血。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Angiotensin II is an endogenous hormone with vasopressor and endocrine activities. This is a systematic review of the safety of IV angiotensin II.

DATA SOURCES: PubMed, Medline, Scopus, and Cochrane.

STUDY SELECTION: Studies in which human subjects received IV angiotensin II were selected whether or not safety was discussed.

DATA EXTRACTION: In total, 18,468 studies were screened by two reviewers and one arbiter. One thousand one hundred twenty-four studies, in which 31,281 participants received angiotensin II (0.5-3,780 ng/kg/min), were selected. Data recorded included number of subjects, comorbidities, angiotensin II dose and duration, pressor effects, other physiologic and side effects, and adverse events.

DATA SYNTHESIS: The most common nonpressor effects included changes in plasma aldosterone, renal function, cardiac variables, and electrolytes. Adverse events were infrequent and included headache, chest pressure, and orthostatic symptoms. The most serious side effects were exacerbation of left ventricular failure in patients with congestive heart failure and bronchoconstriction. One patient with congestive heart failure died from refractory left ventricular failure. Refractory hypotensive shock was fatal in 55 of 115 patients treated with angiotensin II in case studies, cohort studies, and one placebo-controlled study. One healthy subject died after a pressor dose of angiotensin II was infused continuously for 6 days. No other serious adverse events attributable to angiotensin II were reported. Heterogeneity in study design prevented meta-analysis.

CONCLUSION: Adverse events associated with angiotensin II were infrequent; however, exacerbation of asthma and congestive heart failure and one fatal cerebral hemorrhage were reported. This systematic review supports the notion that angiotensin II has an acceptable safety profile for use in humans.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Busse LW, Wang XS, Chalikonda DM, et al. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Crit Care Med. 2017. PMID: 28489648. doi:10.1097/CCM.0000000000002441

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。